{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:25:03Z","timestamp":1781799903065,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971390"],"award-info":[{"award-number":["31971390"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Department of Science and Technology | Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024zd031"],"award-info":[{"award-number":["2024zd031"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the International Science and Technology Innovation Cooperation Project of Sichuan Province"},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYJC21043"],"award-info":[{"award-number":["ZYJC21043"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41375-025-02832-y","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:43:21Z","timestamp":1766475801000},"page":"348-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In vivo expression of CD3\/CD19 bispecific T-cell engager and \u03b1-PD-L1-Fc enables effective and durable immunotherapy for CD19+\/PD-L1+ leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Yueyao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinling","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4038-9180","authenticated-orcid":false,"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8820-7633","authenticated-orcid":false,"given":"Fukun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7089-6074","authenticated-orcid":false,"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-3190","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3296-3015","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2832_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104.","journal-title":"J Hematol Oncol"},{"key":"2832_CR2","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3324\/haematol.2023.283818","volume":"109","author":"KU Lyons","year":"2024","unstructured":"Lyons KU, Gore L. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Haematologica. 2024;109:1668\u201376.","journal-title":"Haematologica"},{"key":"2832_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M. Blinatumomab: first global approval. Drugs. 2015;75:321\u20137.","journal-title":"Drugs"},{"key":"2832_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"2832_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"T Zheng","year":"2021","unstructured":"Zheng T, Ming L, Ya Z, Xin W. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14:75.","journal-title":"J Hematol Oncol"},{"key":"2832_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1182\/blood-2023-191109","volume":"142","author":"JA Webster","year":"2023","unstructured":"Webster JA, Luskin MR, Rimando J, Blackford A, Zeidan AM, Sharon E, et al. Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study. Blood. 2023;142:966.","journal-title":"Blood"},{"key":"2832_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"T-G Antonio","year":"2023","unstructured":"Antonio T-G, Luis \u00c1-V, Laura S. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16:83.","journal-title":"J Hematol Oncol"},{"key":"2832_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"JD Michael","year":"2022","unstructured":"Michael JD, Carmelo C-S, Franck M, Emmanuel B, Paolo C, Gloria I, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"},{"key":"2832_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep17943","volume":"5","author":"JS Eric","year":"2015","unstructured":"Eric JS, Kara O, Lauric JH, Bindu V, Paurene D, Andrew DT, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015;5:17943.","journal-title":"Sci Rep"},{"key":"2832_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"2832_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nrd.2017.217","volume":"17","author":"J Wagner","year":"2018","unstructured":"Wagner J, Dahlem A, Hudson L, Terry S, Altman R, Gilliland C, et al. A dynamic map for learning, communicating, navigating and improving therapeutic development. Nat Rev Drug Discov. 2018;17:150.","journal-title":"Nat Rev Drug Discov"},{"key":"2832_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ajh.27227","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Zugmaier G, Agrawal V, Mart\u00ednez-S\u00e1nchez P, Rif\u00f3n Roca JJ, Cassaday RD, et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024;99:586\u201395.","journal-title":"Am J Hematol"},{"key":"2832_CR13","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","volume":"12","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, Torrent A, Rif\u00f3n JJ, Agrawal V, et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial. Lancet Haematol. 2025;12:e529\u2013e541.","journal-title":"Lancet Haematol"},{"key":"2832_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843\u201354.","journal-title":"JAMA"},{"key":"2832_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24987","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Dull J, Yilmaz M, Khoury JD, Ravandi F, Jain N, et al. Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018;93:371\u20134.","journal-title":"Am J Hematol"},{"key":"2832_CR16","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.3390\/ijms23063067","volume":"23","author":"K J\u0119draszek","year":"2022","unstructured":"J\u0119draszek K, Malczewska M, Parysek-W\u00f3jcik K, Lejman M. Resistance mechanisms in pediatric B-cell acute lymphoblastic leukemia. Int J Mol Sci. 2022;23:3067.","journal-title":"Int J Mol Sci"},{"key":"2832_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"},{"key":"2832_CR18","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1182\/bloodadvances.2025015894","volume":"9","author":"J Ma","year":"2025","unstructured":"Ma J, Luong A, Doan A, Lin TY, Ji L, Wang CP, et al. T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia. Blood Adv. 2025;9:3689\u201393. 12.","journal-title":"Blood Adv"},{"key":"2832_CR19","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/bloodadvances.2020002403","volume":"4","author":"RD Cassaday","year":"2020","unstructured":"Cassaday RD, Garcia KA, Fromm JR, Percival MM, Turtle CJ, Nghiem PT, et al. Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Adv. 2020;4:3239\u201345.","journal-title":"Blood Adv"},{"key":"2832_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1008\u201319.","journal-title":"JAMA Oncol"},{"key":"2832_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"A De Sousa Linhares","year":"2019","unstructured":"De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci Rep. 2019;9:11472.","journal-title":"Sci Rep"},{"key":"2832_CR22","first-page":"311","volume":"30","author":"C Antonella","year":"2021","unstructured":"Antonella C, Emanuele M, Fabio P, Giuseppe R, Micol R, Valeria F, et al. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther. 2021;30:311\u201326.","journal-title":"Mol Ther"},{"key":"2832_CR23","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.celrep.2018.10.062","volume":"25","author":"P Ami","year":"2018","unstructured":"Ami P, Daniel HP, Carl WD, Trevor RFS, Anders L, Kevin T, et al. In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model. Cell Rep. 2018;25:1982\u201393.","journal-title":"Cell Rep"},{"key":"2832_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00576-7","volume":"8","author":"P Ami","year":"2017","unstructured":"Ami P, Antonio D, Ashley EK, Trevor RFS, Daniel HP, Stephanie R, et al. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nat Commun. 2017;8:637.","journal-title":"Nat Commun"},{"key":"2832_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.addr.2004.12.003","volume":"57","author":"N Makiya","year":"2005","unstructured":"Makiya N, Yoshinobu T, Mitsuru H. Theoretical considerations involving the pharmacokinetics of plasmid DNA. Adv Drug Deliv Rev. 2005;57:675\u201388.","journal-title":"Adv Drug Deliv Rev"},{"key":"2832_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/1566523214666140612154929","volume":"14","author":"HS Chi","year":"2014","unstructured":"Chi HS, Shawn W, Roderick AS. Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy. Curr Gene Ther. 2014;14:309\u201329.","journal-title":"Curr Gene Ther"},{"key":"2832_CR27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/pharmaceutics14091861","volume":"14","author":"DH Mart\u00ednez-Puente","year":"2022","unstructured":"Mart\u00ednez-Puente DH, P\u00e9rez-Trujillo JJ, Zavala-Flores LM, Garc\u00eda-Garc\u00eda A, Villanueva-Olivo A, Rodr\u00edguez-Rocha H, et al. Plasmid DNA for Therapeutic Applications in Cancer. Pharmaceutics. 2022;14:1861.","journal-title":"Pharmaceutics"},{"key":"2832_CR28","doi-asserted-by":"crossref","unstructured":"Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998;16:867\u201370.","DOI":"10.1038\/nbt0998-867"},{"key":"2832_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04547-2","volume":"7","author":"B Todorova","year":"2017","unstructured":"Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, et al. Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Sci Rep. 2017;7:4122.","journal-title":"Sci Rep"},{"key":"2832_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clim.2016.08.021","volume":"171","author":"H Chen","year":"2016","unstructured":"Chen H, Zheng X, Wang R, Gao N, Sheng Z, Fan D, et al. Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection. Clin Immunol. 2016;171:41\u201349.","journal-title":"Clin Immunol"},{"key":"2832_CR31","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.3390\/ijms21186494","volume":"21","author":"EP Spugnini","year":"2020","unstructured":"Spugnini EP, Scimeca M, Amadio B, Cortese G, Fanciulli M, Vincenzi B, et al. Definition of a novel plasmid-based gene transfection protocol of mammalian skeletal muscles by means of in vivo electroporation. Int J Mol Sci. 2020;21:6494.","journal-title":"Int J Mol Sci"},{"key":"2832_CR32","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41596-019-0125-y","volume":"14","author":"M Bez","year":"2019","unstructured":"Bez M, Foiret J, Shapiro G, Pelled G, Ferrara KW, Gazit D. Nonviral ultrasound-mediated gene delivery in small and large animal models. Nat Protoc. 2019;14:1015\u201326.","journal-title":"Nat Protoc"},{"key":"2832_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jconrel.2015.12.001","volume":"223","author":"G Shapiro","year":"2016","unstructured":"Shapiro G, Wong AW, Bez M, Yang F, Tam S, Even L, et al. Multiparameter evaluation of in vivo gene delivery using ultrasound-guided, microbubble-enhanced sonoporation. J Control Release. 2016;223:157\u201364.","journal-title":"J Control Release"},{"key":"2832_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2014.03.021","volume":"183","author":"K Nagata","year":"2014","unstructured":"Nagata K, Itaka K, Baba M, Uchida S, Ishii T, Kataoka K. Muscle-targeted hydrodynamic gene introduction of insulin-like growth factor-1 using polyplex nanomicelle to treat peripheral nerve injury. J Control Release. 2014;183:27\u201334.","journal-title":"J Control Release"},{"key":"2832_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2021.100192","volume":"13","author":"L Gui","year":"2022","unstructured":"Gui L, Chen Y, Diao Y, Chen Z, Duan J, Liang X, et al. ROS-responsive nanoparticle-mediated delivery of CYP2J2 gene for therapeutic angiogenesis in severe hindlimb ischemia. Mater Today Bio. 2022;13:100192.","journal-title":"Mater Today Bio"},{"key":"2832_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2019.105204","volume":"186","author":"D Peri","year":"2020","unstructured":"Peri D, Deville M, Poignard C, Signori E, Natalini R. Numerical optimization of plasmid DNA delivery combined with hyaluronidase injection for electroporation protocol. Comput Methods Prog Biomed. 2020;186:105204.","journal-title":"Comput Methods Prog Biomed"},{"key":"2832_CR37","doi-asserted-by":"publisher","first-page":"7282","DOI":"10.1021\/acsami.5b00486","volume":"7","author":"J Chen","year":"2015","unstructured":"Chen J, Luo J, Zhao Y, Pu L, Lu X, Gao R, et al. Increase in transgene expression by pluronic L64-mediated endosomal\/lysosomal escape through its membrane-disturbing action. ACS Appl Mater Interfaces. 2015;7:7282\u201393.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2832_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.plasmid.2019.102441","volume":"106","author":"Y Liu","year":"2019","unstructured":"Liu Y, He Y, Wang Y, Liu M, Jiang M, Gao R, et al. Synthetic promoter for efficient and muscle-specific expression of exogenous genes. Plasmid. 2019;106:102441.","journal-title":"Plasmid"},{"key":"2832_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/rb\/rby028","volume":"6","author":"Y He","year":"2019","unstructured":"He Y, Liu Y, Sun Z, Han F, Tang JZ, Gao R, et al. The proper strategy to compress and protect plasmid DNA in the Pluronic L64-electropulse system for enhanced intramuscular gene delivery. Regen Biomater. 2019;6:289\u201398.","journal-title":"Regen Biomater"},{"key":"2832_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.gendis.2022.05.009","volume":"10","author":"L Deng","year":"2023","unstructured":"Deng L, Yang P, Li C, Xie L, Lu W, Zhang Y, et al. Prolonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue. Genes Dis. 2023;10:1101\u201313.","journal-title":"Genes Dis"},{"key":"2832_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2337\/db22-0860","volume":"72","author":"L Xie","year":"2023","unstructured":"Xie L, Lu W, Zhang Y, Deng L, Liu M, Gao H, et al. Glucose-activated switch regulating insulin analog secretion enables long-term precise glucose control in mice with type 1 diabetes. Diabetes. 2023;72:703\u201314.","journal-title":"Diabetes"},{"key":"2832_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"2832_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:539\u201360.","journal-title":"Nat Rev Clin Oncol"},{"key":"2832_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"2832_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381:455\u201364.","journal-title":"N Engl J Med"},{"key":"2832_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3550","volume":"25","author":"B Cesur-Ergun","year":"2023","unstructured":"Cesur-Ergun B, Demir-Dora D. Gene therapy in cancer. J Gene Med. 2023;25:e3550.","journal-title":"J Gene Med"},{"key":"2832_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00634-4","volume":"12","author":"W Lei","year":"2022","unstructured":"Lei W, Ye Q, Hao Y, Chen J, Huang Y, Yang L, et al. CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma. Blood Cancer J. 2022;12:35.","journal-title":"Blood Cancer J"},{"key":"2832_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.","journal-title":"Mol Cancer"},{"key":"2832_CR49","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32:4235\u201355.","journal-title":"Mol Ther"},{"key":"2832_CR50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/14712598.2017.1294156","volume":"17","author":"G Hamilton","year":"2017","unstructured":"Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017;17:515\u201323.","journal-title":"Expert Opin Biol Ther"},{"key":"2832_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","volume":"42","author":"A Hodder","year":"2024","unstructured":"Hodder A, Mishra AK, Enshaei A, Baird S, Elbeshlawi I, Bonney D, et al. Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol. 2024;42:907\u201314.","journal-title":"J Clin Oncol"},{"key":"2832_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0977-3","volume":"18","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Sun R, Zhao HJ, Fu D, Zhong HJ, Weng XQ, et al. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol Cancer. 2019;18:54.","journal-title":"Mol Cancer"},{"key":"2832_CR53","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O\u2019Donnell M, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92:858\u201365.","journal-title":"Am J Hematol"},{"key":"2832_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129:100\u20134.","journal-title":"Blood"},{"key":"2832_CR55","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154\u20137.","journal-title":"Blood"},{"key":"2832_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm1890","volume":"8","author":"TP Cripe","year":"2022","unstructured":"Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, et al. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv. 2022;8:eabm1890.","journal-title":"Sci Adv"},{"key":"2832_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01036-4","volume":"14","author":"Z Song","year":"2024","unstructured":"Song Z, Liu P, Zhang D, Wang T, Yue W, Geng Y, et al. In vivo expression of anti-CD19\/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies. Blood Cancer J. 2024;14:46.","journal-title":"Blood Cancer J"},{"key":"2832_CR58","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.ymthe.2020.02.007","volume":"28","author":"L Jacobs","year":"2020","unstructured":"Jacobs L, De Smidt E, Geukens N, Declerck P, Hollevoet K. DNA-based delivery of checkpoint inhibitors in muscle and tumor enables long-term responses with distinct exposure. Mol Ther. 2020;28:1068\u201377.","journal-title":"Mol Ther"},{"key":"2832_CR59","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","volume":"27","author":"Y Rybakova","year":"2019","unstructured":"Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol Ther. 2019;27:1415\u201323.","journal-title":"Mol Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02832-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02832-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02832-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:03:13Z","timestamp":1770278593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02832-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2832"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02832-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Prior to collecting blood samples from the B-ALL patient, informed consent was obtained after fully explaining the purpose, procedures, and potential consequences of the study. All animal experiments were conducted in accordance with ethical standards and approved by the Biomedical Research Ethics Committee of West China Hospital, Sichuan University (2022-1404).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the final version of the manuscript and have consented to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}